Abstract:The accumulation of uremic toxins (UTs) is a prototypical manifestation of uremic milieu that follows renal function decline (chronic kidney disease, CKD). Frailty as a potential outcome-relevant indicator is also prevalent in CKD. The intertwined relationship between uremic toxins, including small/large solutes (phosphate, asymmetric dimethylarginine) and protein-bound ones like indoxyl sulfate (IS) and p-cresyl sulfate (pCS), and frailty pathogenesis has been documented recently. Uremic toxins were shown in vitro and in vivo to induce noxious effects on many organ systems and likely influenced frailty development through their effects on multiple preceding events and companions of frailty, such as sarcopenia/muscle wasting, cognitive impairment/cognitive frailty, osteoporosis/osteodystrophy, vascular calcification, and cardiopulmonary deconditioning. These organ-specific effects may be mediated through different molecular mechanisms or signal pathways such as peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), mitogen-activated protein kinase (MAPK) signaling, aryl hydrocarbon receptor (AhR)/nuclear factor-κB (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), Runt-related transcription factor 2 (RUNX2), bone morphogenic protein 2 (BMP2), osterix, Notch signaling, autophagy effectors, microRNAs, and reactive oxygen species induction. Anecdotal clinical studies also suggest that frailty may further accelerate renal function decline, thereby augmenting the accumulation of UTs in affected individuals. Judging from these threads of evidence, management strategies aiming for uremic toxin reduction may be a promising approach for frailty amelioration in patients with CKD. Uremic toxin lowering strategies may bear the potential of improving patients' outcomes and restoring their quality of life, through frailty attenuation. Pathogenic molecule-targeted therapeutics potentially disconnect the association between uremic toxins and frailty, additionally serving as an outcome-modifying approach in the future.

Progress of Middle Molecular Weight Uremic Toxins and Removal Techniques

Derivation and Elimination of Uremic Toxins from Kidney-Gut Axis

Middle Molecular Uremic Toxin and Blood Purification Therapy

Effect of Single Hemoperfusion Combined with Hemodialysis on Macromolecular Uremic Toxin

Advances in uremic toxin detection and monitoring in the management of chronic kidney disease progression to end-stage renal disease

Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives

Future of Uremic Toxin Management

Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets

Rationale for a New Classification of Solutes of Interest in Chronic Kidney Disease and Hemodialysis

Reticular Access to Triptycene-Based Cationic Metal–organic Frameworks for Protein-Bound Uremic Toxins Sorption

Classification of Uremic Toxins and Their Role in Kidney Failure

Adsorption-based strategies for removing uremic toxins from blood

A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease

Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System

Adsorption Dynamics of Uremic Toxins to Cyclodextrin-Coated Magnetic Nano-Adsorbents

Progress in Hemoperfusion Adsorbents of Common Toxins in Liver and Kidney Failure

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites

Proposal for a New Classification of Solutes of Interest in Uremia and Hemodialysis

Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients

Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight

Uremic Toxins Are Conditional Danger- or Homeostasis-Associated Molecular Patterns.